BAKER BROS. ADVISORS LP: KYMERA THERAPEUTICS INC (KYMR): Quarterly 13F Position History
As of Q1 2026, BAKER BROS. ADVISORS LP reported 8,657,242 shares of KYMERA THERAPEUTICS INC (KYMR), worth $721.1M and representing 4.1% of its 13F equity book. The position first appeared in Q3 2020 and has been disclosed across 23 13F-HR filings in Pactolio's tracked window.
- 8,657,242Shares Held (Latest Filing)
- $721.1MReported Market Value (Latest Filing)
- 4.1%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$47.4MQuarter-over-Quarter Value Change
- 8,657,242Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 23 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 8,657,242 | 0 | — | $721.1M | 4.1% | $83.3 |
| Q4 2025 | 8,657,242 | +2,005,813 | +30.2% | $673.6M | 3.9% | $77.8 |
| Q3 2025 | 6,651,429 | 0 | — | $376.5M | 2.7% | $56.6 |
| Q2 2025 | 6,651,429 | +655,500 | +10.9% | $290.3M | 2.8% | $43.6 |
| Q1 2025 | 5,995,929 | 0 | — | $164.1M | 1.8% | $27.4 |
| Q4 2024 | 5,995,929 | 0 | — | $241.2M | 2.6% | $40.2 |
| Q3 2024 | 5,995,929 | +1 | +0.0% | $283.8M | 2.9% | $47.3 |
| Q2 2024 | 5,995,928 | 0 | — | $179.0M | 2.3% | $29.9 |
| Q1 2024 | 5,995,928 | 0 | — | $241.0M | 3.0% | $40.2 |
| Q4 2023 | 5,995,928 | +1,245,528 | +26.2% | $152.7M | 1.7% | $25.5 |
| Q3 2023 | 4,750,400 | +375,060 | +8.6% | $66.0M | 0.4% | $13.9 |
| Q2 2023 | 4,375,340 | +1,495,515 | +51.9% | $100.6M | 0.6% | $23.0 |
| Q1 2023 | 2,879,825 | 0 | — | $85.3M | 0.5% | $29.6 |
| Q4 2022 | 2,879,825 | 0 | — | $71.9M | 0.4% | $25.0 |
| Q3 2022 | 2,879,825 | 0 | — | $62.7M | 0.4% | $21.8 |
| Q2 2022 | 2,879,825 | +495,083 | +20.8% | $56.7M | 0.3% | $19.7 |
| Q1 2022 | 2,384,742 | 0 | — | $100.9M | 0.6% | $42.3 |
| Q4 2021 | 2,384,742 | 0 | — | $151.4M | 0.7% | $63.5 |
| Q3 2021 | 2,384,742 | +425,531 | +21.7% | $140.1M | 0.6% | $58.7 |
| Q2 2021 | 1,959,211 | 0 | — | $95.0M | 0.4% | $48.5 |
| Q1 2021 | 1,959,211 | 0 | — | $76.1M | 0.3% | $38.9 |
| Q4 2020 | 1,959,211 | 0 | — | $121.5M | 0.5% | $62.0 |
| Q3 2020 | 1,959,211 | — | — | $63.3M | 0.3% | $32.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did BAKER BROS. ADVISORS LP first disclose a KYMR position in 13F-HR filings?
BAKER BROS. ADVISORS LP first reported KYMERA THERAPEUTICS INC (KYMR) on its 13F-HR filing for the period ending 2020-09-30 (Q3 2020). The position has appeared on 23 reported quarters within Pactolio's tracked window.
What was BAKER BROS. ADVISORS LP's most recent quarter-over-quarter share-count change in KYMR?
BAKER BROS. ADVISORS LP held the same 8,657,242 shares of KYMR between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent BAKER BROS. ADVISORS LP's cost basis in KYMR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.